An experimental COVID-19 attraction pill called molnupiravir being developed by Merck and Ridgeback Biotherapeutics, is seen successful this an undated photograph. (Merck/Reuters)
AMSTERDAM—The pharmaceutical institution Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the archetypal pill that has been shown to dainty the disease.
In a connection connected Monday, Merck said the EU cause regulator had started an expedited licensing process for molnupiravir. If fixed the greenish light, it would beryllium the archetypal attraction for COVID-19 that does not request to beryllium administered done needles oregon intravenous infusions.
Earlier this month, Merck asked the U.S. Food and Drug Administration to OK molnupiravir, and a determination is expected wrong weeks.
The institution reported this period that the pill chopped hospitalizations and deaths by fractional among patients with aboriginal symptoms of COVID-19. The results were truthful beardown that autarkic aesculapian experts monitoring the proceedings recommended stopping it early.
An antiviral pill that radical could instrumentality astatine location to trim their symptoms and velocity betterment could beryllium groundbreaking, easing the crushing caseload connected hospitals and helping to curb outbreaks successful poorer countries with anemic wellness attraction systems.